Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination

Sakayori, Masashi; Hagiwara, Eri; Baba, Tomohisa; Kitamura, Hideya; Sekine, Akimasa; Ikeda, Satoshi; Tabata, Erina; Yamada, Sho; Fujimoto, Kazushi; Ogura, Takashi

doi:10.1016/j.jiac.2022.09.006

Cited by 8 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of them (233 patients, 44.4%) were vaccinated more than once. However, the study of Sakayori, and so on indicated that the safety of COVID‐19 vaccination for patients with ILD was acceptable 14 . After receiving the mRNA COVID‐19 vaccination in 545 patients with ILD, 17 patients (3.1%) suffered from exacerbation of respiratory symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…However, considering the adverse events of the vaccine, including vaccination‐induced ILD, refractory or acute exacerbation (AE) of pre‐existing ILD, or flare of underlying CTD, it has not been widely received in patients with autoimmune involvement ILD (such as CTD‐ILD, IPAF, sarcoidosis, etc.) and severe fibrosing ILD 13–17 …”

Section: Introductionmentioning

confidence: 99%

“…and severe fibrosing ILD. [13][14][15][16][17] The characteristics of COVID-19 pneumonia in patients with A total of 662 patients with ILD visited our ILD clinic during the enrollment period. Among them, 107 patients were diagnosed with ILD for the first time.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Shao,

Shi,

Chen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

In China, the emergence of a nationally widespread epidemic infection of severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) has appeared within a month since December 7, 2022. To evaluate the risk factors for suffering from coronavirus disease 2019 (COVID‐19) pneumonia due to infection with SARS‐CoV‐2 in different kinds of interstitial lung disease (ILD) patients with diverse immunizations, we conducted this retrospective study on 525 patients with ILDs who underwent regular follow‐up in our ILD clinic. Among them, 128 ILD patients (24.4%) suffered from COVID‐19 pneumonia after SARS‐CoV‐2 infection. Patients were older with a male predominance in the pneumonia group than in the nonpneumonia group (65.0 ± 10.0 years vs. 56.4 ± 11.7 years, p < 0.001, 55.5% vs. 39.5%, p = 0.002, respectively). Connective tissue disease‐associated ILD (CTD‐ILD) (25%), idiopathic pulmonary fibrosis (23.4%), and interstitial pneumonia with autoimmune features (21.1%) were the main pre‐existing ILDs in the pneumonia group. In Cox multivariable analysis, only male sex and corticosteroid use were risk factors for COVID‐19 pneumonia after infection. Two or three doses of vaccination were a protective factor for pre‐existing ILD patients suffering from COVID‐19 pneumonia. More than two doses of vaccination were strongly recommended for pre‐existing ILD patients, particularly for males who were administered corticosteroids.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Shao,

Shi,

Chen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Several mutants of SARS-CoV-2 were subsequently detected as the prevailing strains in the past few years. Although its mortality rate (around 2%) was much lower than that of SARS, COVID-19 was found to be highly contagious, with many asymptomatic or mild patients in their first infection, which might turn out to be a great threat to human health in the following years [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Strictinin, a Major Ingredient in Yunnan Kucha Tea Possessing Inhibitory Activity on the Infection of Mouse Hepatitis Virus to Mouse L Cells

Hsu

Tzen

2023

Molecules

View full text Add to dashboard Cite

Theacrine and strictinin of Yunnan Kucha tea prepared from a mutant variety of wild Pu’er tea plants were two major ingredients responsible for the anti-influenza activity. As the COVID-19 outbreak is still lurking, developing safe and cost-effective therapeutics is an urgent need. This study aimed to evaluate the effects of these tea compounds on the infection of mouse hepatitis virus (MHV), a β-coronavirus serving as a surrogate for SARS-CoV. Treatment with strictinin (100 μM), but not theacrine, completely eliminated MHV infection, as indicated by a pronounced reduction in plaque formation, nucleocapsid protein expression, and progeny production of MHV. Subsequently, a time-of-drug addition protocol, including pre-, co-, or post-treatment, was exploited to further evaluate the possible mechanism of antiviral activity mediated by strictinin, and remdesivir, a potential drug for the treatment of SARS-CoV-2, was used as a positive control against MHV infection. The results showed that all three treatments of remdesivir (20 μM) completely blocked MHV infection. In contrast, no significant effect on MHV infection was observed when cells were pre-treated with strictinin (100 μM) prior to infection, while significant inhibition of MHV infection was observed when strictinin was introduced upon viral adsorption (co-treatment) and after viral entry (post-treatment). Of note, as compared with the co-treatment group, the inhibitory effect of strictinin was more striking in the post-treatment group. These results indicate that strictinin suppresses MHV infection by multiple mechanisms; it possibly interferes with viral entry and also critical step(s) of viral infection. Evidently, strictinin significantly inhibited MHV infection and might be a suitable ingredient for protection against coronavirus infection.

show abstract

“…COVID-19 vaccination has been proven highly effective in preventing the onset of SARS-CoV-2 infection and may reduce the incidence of COVID-19–triggered AE-ILD [ 6 ]. However, a rare case of AE-IPF following conventional monovalent mRNA COVID-19 vaccination has been reported [ [7] , [8] , [9] , [10] ]. Bivalent vaccines, tozinameran and famtozinameran, against omicron strains of COVID-19 became available in Japan in September 2022 and are expected to be more effective in preventing severe disease, infection, and disease onset against omicron strains of COVID-19 than conventional monovalent vaccines.…”

Section: Introductionmentioning

confidence: 99%

Acute exacerbation of idiopathic pulmonary fibrosis after bivalent {tozinameran and famtozinameran} mRNA COVID-19 vaccination

Tsumura,

Zaizen,

Umemoto

et al. 2023

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination

Cited by 8 publications

References 14 publications

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Strictinin, a Major Ingredient in Yunnan Kucha Tea Possessing Inhibitory Activity on the Infection of Mouse Hepatitis Virus to Mouse L Cells

Acute exacerbation of idiopathic pulmonary fibrosis after bivalent {tozinameran and famtozinameran} mRNA COVID-19 vaccination

Contact Info

Product

Resources

About